VAL vs. IXI, BSFA, OCTP, GENF, FAB, APTA, ROQ, EVG, PYC, and NFX
Should you be buying ValiRx stock or one of its competitors? The main competitors of ValiRx include IXICO (IXI), BSF Enterprise (BSFA), Oxford Cannabinoid Technologies (OCTP), Genflow Biosciences (GENF), Fusion Antibodies (FAB), Aptamer Group (APTA), Roquefort Therapeutics (ROQ), Evgen Pharma (EVG), Physiomics (PYC), and Nuformix (NFX). These companies are all part of the "biotechnology" industry.
IXICO (LON:IXI) and ValiRx (LON:VAL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
In the previous week, ValiRx's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.
ValiRx has a net margin of 0.00% compared to ValiRx's net margin of -17.67%. ValiRx's return on equity of -9.85% beat IXICO's return on equity.
IXICO has higher revenue and earnings than ValiRx. IXICO is trading at a lower price-to-earnings ratio than ValiRx, indicating that it is currently the more affordable of the two stocks.
56.9% of IXICO shares are held by institutional investors. Comparatively, 0.1% of ValiRx shares are held by institutional investors. 29.0% of IXICO shares are held by company insiders. Comparatively, 16.1% of ValiRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ValiRx received 6 more outperform votes than IXICO when rated by MarketBeat users. However, 71.64% of users gave IXICO an outperform vote while only 51.55% of users gave ValiRx an outperform vote.
IXICO has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, ValiRx has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Summary
IXICO beats ValiRx on 9 of the 12 factors compared between the two stocks.
Get ValiRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
